<?xml version="1.0" encoding="UTF-8"?>
<p>In September 2015, the World Health Organization (WHO) recommended ART irrespective of CD4 count (EAAA) [
 <xref rid="jia225610-bib-0010" ref-type="ref">10</xref>]. As high‐prevalence countries adopt these new guidelines, the MaxART trial offers evidence about the “real‐world” impact on retention and viral suppression under an EAAA approach. This trial is registered at clinicaltrials.gov (NCT02909218).
</p>
